HC Wainwright Increases AnaptysBio (NASDAQ:ANAB) Price Target to $66.00

AnaptysBio (NASDAQ:ANAB) had its price objective hoisted by analysts at HC Wainwright from $51.00 to $66.00 in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 15.22% from the company’s current price. HC Wainwright also issued estimates for AnaptysBio’s FY2030 earnings at $7.67 EPS.

Other equities research analysts have also recently issued reports about the company. Barclays lifted their price objective on AnaptysBio from $55.00 to $78.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Wells Fargo & Company lifted their price target on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Stifel Nicolaus reduced their price objective on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Truist Financial raised their price objective on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a report on Monday, November 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $71.89.

AnaptysBio Price Performance

AnaptysBio stock opened at $57.28 on Wednesday. The stock has a market capitalization of $1.65 billion, a PE ratio of -110.15 and a beta of 0.32. The business has a 50 day simple moving average of $50.17 and a 200-day simple moving average of $38.78. AnaptysBio has a 12 month low of $15.32 and a 12 month high of $63.47.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. On average, equities research analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a share buyback program on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, insider Eric J. Loumeau sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the sale, the insider owned 12,835 shares of the company’s stock, valued at approximately $693,090. This represents a 43.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Daniel Faga sold 14,281 shares of AnaptysBio stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares in the company, valued at $21,431,470.24. This trade represents a 2.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 156,280 shares of company stock worth $7,254,939. 33.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 18,165 shares during the last quarter. Savant Capital LLC purchased a new stake in AnaptysBio in the second quarter valued at $241,000. Los Angeles Capital Management LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $334,000. Creative Planning lifted its stake in shares of AnaptysBio by 26.9% in the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after purchasing an additional 3,571 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of AnaptysBio during the 2nd quarter worth $240,000.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.